INNOVATE≥3 IA-05 EUP ≥3 CSS 1.2619 0.6190 exacerbations exacerbations exacerbations (0.9618 to 1.6518) (0.3732 to 1.0269) () () Treatment 46.51% INNOVATE≥3 IA-05 EUP ≥3 Proportion of 77.08% (35.97% to exacerbations exacerbations responders (68.68% to 85.45%) 57.05%) () () Risk for INNOVATE≥3 IA-05 EUP ≥3 CSNS 0.3565 0.2269 exacerbations exacerbations exacerbations (0.2126 to 0.5978) (0.1433 to 0.3592) () () (responders) Risk ratio for INNOVATE≥3 IA-05 EUP ≥3 CSS 0.1840 0.2838 exacerbations exacerbations exacerbations (0.0735 to 0.4602) (0.1157 to 0.6960) () () (responders) Mortality UK life-tables UK life-tables All-cause adjusted for ONS() adjusted for ONS() mortality asthma-related deaths. deaths. Asthma-related Asthma-related mortality rate = 0.4 De et al De Vries et al mortality rate = 0.4 deaths per 100 (2010) () (2010) () per 100 person-years years HRQoL HRQoL difference EXALT EXALT ≥3 ≥3 Omalizumab observed in the exacerbations No HRQoL difference exacerbations effect on trial () between treatments () HRQoL 0.740 up to age 12. (omalizumab)
CSS exacerbations 1.2619 (0.9618 to 1.6518) INNOVATE≥3 exacerbations () 0.6190 (0.3732 to 1.0269) IA-05 EUP ≥3 exacerbations () Treatment Proportion of responders 46.51% (35.97% to 57.05%) INNOVATE≥3 exacerbations () 77.08% (68.68% to 85.45%) IA-05 EUP ≥3 exacerbations () Risk for CSNS exacerbations (responders) 0.3565 (0.2126 to 0.5978) INNOVATE≥3 exacerbations () 0.2269 (0.1433 to 0.3592) IA-05 EUP ≥3 exacerbations () Risk ratio for CSS exacerbations (responders) 0.1840 (0.0735 to 0.4602) INNOVATE≥3 exacerbations () 0.2838 (0.1157 to 0.6960) IA-05 EUP ≥3 exacerbations () Mortality All-cause mortality UK life-tables adjusted for asthma-related deaths. ONS() UK life-tables adjusted for deaths. ONS() deaths Asthma-related mortality rate = 0.4 per 100 De et al (2010) () Asthma-related mortality rate = 0.4 per 100 person-years De Vries et al (2010) () HRQoL Omalizumab effect on HRQoL HRQoL difference observed in the trial 0.740 (omalizumab) EXALT ≥3 exacerbations () No HRQoL difference between treatments up to age 12. EXALT ≥3 exacerbations () years